Order Article Reprints

Deckmyn O, Poynard T, Bedossa P, Paradis V, Peta V, Pais R, Ratziu V, Thabut D, Brzustowski A, Gautier J-F, et al. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Biomedicines. 2022; 10(3):699. https://doi.org/10.3390/biomedicines10030699

Deckmyn, Olivier, Thierry Poynard, Pierre Bedossa, Valérie Paradis, Valentina Peta, Raluca Pais, Vlad Ratziu, Dominique Thabut, Angelique Brzustowski, Jean-François Gautier, and et al. 2022. "Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19" Biomedicines 10, no. 3: 699. https://doi.org/10.3390/biomedicines10030699

Deckmyn, O., Poynard, T., Bedossa, P., Paradis, V., Peta, V., Pais, R., Ratziu, V., Thabut, D., Brzustowski, A., Gautier, J.-F., Cacoub, P., & Valla, D., on behalf of the QUID-NASH, FLIP and PROCOP Research Groups. (2022). Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Biomedicines, 10(3), 699. https://doi.org/10.3390/biomedicines10030699